Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
26 September 2022 - 3:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month September 2022
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes
¨ No x
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes
¨ No x
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
TABLE OF CONTENTS
Item |
|
Sequential Page Number |
|
|
|
1. |
Other Relevant Information, dated September
25, 2022 |
|
3 |
![GRAPHIC](https://content.edgar-online.com/edgar_conv_img/2022/09/26/0001104659-22-102852_tm2226634d1_6kimg001.jpg)
|
Grifols, S.A.
Avinguda de la Generalitat 152
-
158
08174 Sant Cugat del Vallès
Barcelona
-
ESPAÑA
Tel. [34]
935 710 500
Fax [34] 935 710 267
www.grifols.com
P
ursuant
to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved
by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the
following
:
OTHER RELEVANT INFORMATION
In
the
cont
ext of
considerable
g
eopolitical uncertainty and market volatility
, the Board of Directors of
Grifols, S.A
communicates the following:
-
Grifols advance
s
firmly in the execution of a strategic growth plan which continues to create
sustainable value for all
its shareholders.
The company’s fundamentals
remain
solid and robust
.
-
The development of key Biotest innovation projects continues advancing and
,
assuming
the
two
new protein products
IgM and fibrinogen
receive regulatory approval and are
fully
rolled out into
the market,
these products are
expected to
contribute significantly to
Grifols’
operating profit.
These projects complement Grifols’ current
innovation
projects
and
contribute to the company’s
soli
d
product development
pipeline
.
-
The
volume of
plasma
collection
has
rebounded
from pandemic lows
. S
ince May
2022
, monthly
plasma
collection volume
s
have been
exceeding the average monthly collection volume in
2019
.
The
company is
also
actively working
on
operating
cost reductions
,
as well as
continuous
improvement
in
operational efficiencies
while re
building
inventory
.
Increased plasma collection
has in turn driven r
evenue growth; the company forecasts revenues for the second half of 2022 to
be
up by a double digit percentage amount compared to the second half of 2021.
-
The strategic agreement to
increase
self
-
sufficie
ncy in Canada
strengthens
Grifols’ positioning as
partner
of choice
in a pioneering public
-
private collaboration model in the industry
, which together
with that of Egypt, could be replicated in other countries.
-
The re
organization
of the company
’s
organizational structure and
operational processes
,
to
accelerate greater agility and focus on the business units,
has already been implemented.
-
At the same time,
Grifols continues
to
attract
highly qualified
talent
,
with
two new execut
ives with
recognized international careers
expected to
join
the company
to manage the Biopharma and
Plasma
Procurement
business units.
Further detail will be provided shortly
.
-
We reiterate
this Board’s
commitment
to reduce debt levels
. The
B
oard is evaluating several
strategic alternatives to achieve that goal
while also
improv
ing
the company’s
cash flow profile
.
The
B
oard also notes that the company had cash and unrestricted revolver borrowing capacity
totaling
over EUR
1.3
billion as of August 31, 2022.
In
all its
endeavors, the
B
oard is keenly focused
on increasing
value for all shareholders.
|
![GRAPHIC](https://content.edgar-online.com/edgar_conv_img/2022/09/26/0001104659-22-102852_tm2226634d1_6kimg002.jpg)
|
-
Grifols plans to
continue
to enhance
the frequency and effectiveness of Grifols’
communications.
We would like
also
to announce th
at
commencing with the first quarter of
2023, Grifols will
publish
quarterly earnings reports.
In Barcelona
,
on
September 25,
2022
President
of
the Board of Directors
Lead Independent Director
Víctor Grífols Roura
Carina
Szpilka
Legal
Disclaimer.
This communication contains forward
-
looking information and statements about
Grifols based on current assumptions and forecasts made by Grifols
management, including statements
regarding plans, objectives and expectations with respect to products, operating efficiencies, debt
levels,
strategy and
management
, and statements regarding future performance. Forward
-
looking
statements are statements th
at are not historical facts and are
generally identified by the word
“expected” and similar expressions.
Although Grifols believes that the expectations reflected in such forward
-
looking statements are
reasonable, various known and unknown risks, uncertain
ties
and other factors could lead to material
differences between the actual future results, financial situation, development or performance of the
company and/or its products, and the expectations set forth in this communication.
These factors
include
tho
se discussed in our public reports filed with the Comision Nacional del Mercado
de Valores and the Securities and Exchange Commission, which are accessible to the public. The
company assumes no liability
whatsoever to update these forward
-
looking statement
s or conform them
to future events of developments.
Forward
-
looking statements are not guarantees of future
performance.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A. |
|
|
|
|
By: |
/s/
David I. Bell |
|
|
Name: |
David I. Bell |
|
|
Title: |
Authorized Signatory |
Date: September 26, 2022
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Grifols SA (PK) (OTCMarkets): 0 Nachrichtenartikel
Weitere Grifols Sa News-Artikel